Literature DB >> 16183016

A role for RKIP in cell motility.

William M Bement1.   

Abstract

The target of locostatin, a small-molecule inhibitor of cell movement, has been identified as RKIP, a Raf-1 kinase modulator [1]. In addition to advancing our understanding of cell locomotion, this work represents a major landmark in the development of chemical genetics.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16183016     DOI: 10.1016/j.chembiol.2005.08.012

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  5 in total

1.  Clinicopathological features and prognostic implications of Raf kinase inhibitor protein downregulation in tongue squamous cell carcinoma.

Authors:  Fengchun Hu; Xiaohua Chen; Xiqiang Liu; Cheng Wang; Lanhai Lv; Nan Xie; Tianyi Wang; Hongzhang Huang
Journal:  Oncol Lett       Date:  2015-07-15       Impact factor: 2.967

2.  Downregulation of RKIP is associated with poor outcome and malignant progression in gliomas.

Authors:  Olga Martinho; Sara Granja; Teresa Jaraquemada; Cláudia Caeiro; Vera Miranda-Gonçalves; Mrinalini Honavar; Paulo Costa; Margarida Damasceno; Marsha R Rosner; José M Lopes; Rui M Reis
Journal:  PLoS One       Date:  2012-01-23       Impact factor: 3.240

Review 3.  Current Status of Raf Kinase Inhibitor Protein (RKIP) in Lung Cancer: Behind RTK Signaling.

Authors:  Ana Raquel-Cunha; Diana Cardoso-Carneiro; Rui M Reis; Olga Martinho
Journal:  Cells       Date:  2019-05-10       Impact factor: 6.600

Review 4.  RKIP as an Inflammatory and Immune System Modulator: Implications in Cancer.

Authors:  Maria Gabriela-Freitas; Joana Pinheiro; Ana Raquel-Cunha; Diana Cardoso-Carneiro; Olga Martinho
Journal:  Biomolecules       Date:  2019-11-22

5.  RKIP inhibition in cervical cancer is associated with higher tumor aggressive behavior and resistance to cisplatin therapy.

Authors:  Olga Martinho; Filipe Pinto; Sara Granja; Vera Miranda-Gonçalves; Marise A R Moreira; Luis F J Ribeiro; Celso di Loreto; Marsha R Rosner; Adhemar Longatto-Filho; Rui Manuel Reis
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.